Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Your commitment strengthens our ability to report fearlessly on the topics that matter most to you.

About a dozen activists from the Extinction Rebellion climate group briefly occupied the entrance lobby of French bank BNP ...

(Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs ...

The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This ...

After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs, some U.S.

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.